23 Papers
186 Citations
Robert E. Boyd is an academic researcher from Johnson & Johnson Pharmaceutical Research and Development. The author has contributed to research in topics: Cardiovascular agent & Agonist. The author has an hindex of 10, co-authored 23 publications. Previous affiliations of Robert E. Boyd include Janssen Pharmaceutica.
Chat about Author
Papers
α2 Adrenoceptor Agonists as Potential Analgesic Agents. 3. Imidazolylmethylthiophenes
Robert E. Boyd,C. Royce Rasmussen,Jeffery B. Press,Robert B. Raffa,Ellen E. Codd,Charlene D. Connelly,Quan S. Li,Rebecca P. Martinez,Martin A. Lewis,Harold R. Almond,Allen B. Reitz +10 more
TL;DR: A pharmacophore model based on the biological activity of the present series of imidazolylmethylthiophenes, dexmedetomidine, and conformationally restrained analogues 3 and 4 is constructed and excellent binding at the alpha(2D) adrenoceptor is found.
37
Piperazinylalkyl heterocycles as potential antipsychotic agents
Malcolm K. Scott,E. W. Baxter,Debra J. Bennett,Robert E. Boyd,P. S. Blum,E. E. Codd,Kukla Mj,E. A. Malloy,Bruce E. Maryanoff,Cynthia A. Maryanoff +9 more
TL;DR: The CAR activities of pyrroles 6 and 12, thiophene 40, furans 44-47, isoxazolines 49 and 50, and pyridine 54 coupled with their weak or nonexistent D2 binding and strong 5-HT1A binding suggest that they may be acting via a nondopaminergic mechanism or that dopaminergic active metabolites are responsible.
36
Patent
3-(diarylmethylene)-8-azabicyclo[3.2.1]octane derivatives
Robert E. Boyd,John R. Carson,Steven J. Coats,Lou Anne Neilson,Philip M. Pitis,Wu-Nan Wu +5 more
- 22 Feb 2001
TL;DR: In this article, a 3-(diarylmethylene)-8-azabicyclo[3.2.1] octane derivatives are used as δ-opioid or μ-OPIOid receptor modulators.
35
Synthesis of (−)-5,8-Dihydroxy-3R-methyl-2R-(dipropylamino)-1,2,3,4-tetrahydronaphthalene: An Inhibitor of β-Amyloid1–42 Aggregation
Michael H. Parker,Chen Robert H,Kelly A. Conway,Daniel H. S. Lee,Chi Luo,Robert E. Boyd,Samuel O Nortey,Tina Morgan Ross,Malcolm K. Scott,Allen B. Reitz +9 more
TL;DR: Hydroquinone is a potent inhibitor of the fibrillar aggregation of beta-amyloid as determined in two different assay systems.
26
Synthesis and binding affinities of 4-diarylaminotropanes, a new class of delta opioid agonists.
TL;DR: The 4-diarylaminotropanes were more potent and selective versus the mu opioid receptor than the exo isomers and the most potent delta opioid agonist exhibited a delta opioid Ki of 0.2 nM and was 860-fold selective over mu.
18